HIGH IMPACT - Chinese biotech I-Mab announced that its U.S. partner AbbVie will discontinue a phase 1b study evaluating a combination treatment for its anti-CD47 antibody therapy lemzoparlimab + venetoclax + azacitidine in MDS and AML. The decision…
https://inthought.com/wp-content/uploads/2022/03/blank-transparent.png720720old adminhttps://inthought.com/wp-content/uploads/2024/09/INThought-Logo-400x250-1-300x188.pngold admin2022-08-17 00:00:112022-09-06 22:11:21AbbVie discontinues phase 1 trial for I-Mab's anti-CD47 therapy in AML and MDS
HIGH IMPACT - Neurocrine announced that the FDA accepted its IND for NBI-1117568 (selective M4 agonist). The company says that it anticipates initiating a Phase 2 study evaluating NBI-1117568 in Schizophrenia in H2 2022. Neurocrine is developing…
https://inthought.com/wp-content/uploads/2022/03/blank-transparent.png720720old adminhttps://inthought.com/wp-content/uploads/2024/09/INThought-Logo-400x250-1-300x188.pngold admin2022-08-09 00:00:472022-09-06 22:19:11Neurocrine to advance selective M4 agonist to Phase 2 for Schizophrenia in the second half of 2022
HIGH IMPACT - Small Pharma announced that the United States Patent and Trademark Office (USPTO) will be issuing a patent for its application pertaining to novel injectable formulations of N,N-dimethyltryptamine (DMT) based compounds including…
https://inthought.com/wp-content/uploads/2022/03/blank-transparent.png720720old adminhttps://inthought.com/wp-content/uploads/2024/09/INThought-Logo-400x250-1-300x188.pngold admin2022-07-28 00:00:212022-08-05 00:51:51Small Pharma Patents Novel Injectable Formulation of its DMT and Other Psychedelic Compounds
MODERATE IMPACT - The FDA placed a clinical hold on the FORTIS phase 1/2 trial of AT845 following a case of peripheral sensory neuropathy in one trial participant. FORTIS is evaluating AT845, an investigational AAV8-based gene replacement…
https://inthought.com/wp-content/uploads/2022/03/blank-transparent.png720720old adminhttps://inthought.com/wp-content/uploads/2024/09/INThought-Logo-400x250-1-300x188.pngold admin2022-06-27 00:00:452022-07-07 17:49:28Astellas’ phase 1/2 FORTIS trial for late-onset Pompe disease placed on FDA clinical hold
MODERATE IMPACT - After a second day of presentations and discussions, the FDA has voted unanimously to endorse betibeglogene autotemcel (beti-cel) for the treatment of patients with beta-thalassemia who require regular red blood cell (RBC)…
https://inthought.com/wp-content/uploads/2022/03/blank-transparent.png720720old adminhttps://inthought.com/wp-content/uploads/2024/09/INThought-Logo-400x250-1-300x188.pngold admin2022-06-10 00:00:042022-07-07 17:44:13FDA unanimously endorses beti-cel for the treatment of beta-thalassemia
HIGH IMPACT - After a full day of presentation and debates around the risk vs benefit of Bluebird Bio's elivaldogene autotemcel (eli-cel) for the treatment of early active cerebral adrenoleukodystrophy (CALD), the FDA unanimously voted to endorse…